Business
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development
About this update from Palvella Therapeutics, Inc.
[{"type":"text","content":"Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved therapies Patent protection extends into 2038 QTORIN™ rapamycin has previously been granted European Orphan Drug Designation for the treatment of microcystic lymphatic malformations, potentially providing 10 years of market exclusivity in the European Union upon approval There are currently no approved therapies in the European Union for microcystic lymphatic malformations WAYNE, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the European Patent Office (EPO) has issued European Patent No. 3565520, which includes claims covering QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), the Company’s lead product candidate from the QTORIN™ platform. The patent provides protection for anhydrous topical compositions and methods of use for QTORIN™ rapamycin, including for the treatment of microcystic lymphatic malformations, venous malformations, and other diseases associated with dysregulation of the mammalian target of rapamycin (mTOR) pathway. “Issuance of this European patent represents an important milestone in expanding our global intellectual property protection for QTORIN™ rapamycin,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics. “Palvella’s exclusivity strategy combines patent protection, multiple layers of innovative formulation know-how and manufacturing trade secrets, and regulatory exclusivities designed to support durable protection for our therapies. This European patent complements our existing issued patents in the United States, Japan, Australia, and other territories covering anhydrous formulations of rapamycin and associated therapeutic uses. In addition, QTORIN™ rapamycin has already been granted Orphan Drug Designation for the treatment of microcystic lymphatic malformations which, if approv...